Form 4: Haemonetics Corp Director Charles J Dockendorff Reports Acquisition of Restricted Stock Units

Director Charles J Dockendorff reports acquisition of 2,207 restricted stock units of Haemonetics Corp.

Summary

• Charles J Dockendorff, a director of Haemonetics Corp, filed a Form 4 on July 26, 2024, reporting a transaction on July 25, 2024.
• Dockendorff acquired 2,207 shares of Common Stock in the form of restricted stock units (RSUs) under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• These RSUs vest 100% on the first anniversary of the grant date.
• Each RSU represents the right to receive one share of Haemonetics Corp's common stock when vested.
• Following the transaction, Dockendorff directly owns 4,433 shares of Common Stock and indirectly owns 17,915 shares through a spouse's revocable trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of insider transactions. The acquisition of shares by a director can be seen as a mildly positive signal.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs on the first anniversary of the grant date suggests a one-year horizon for potential stock ownership.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions, allowing investors to monitor the actions of company executives and directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates